Микробиологическая характеристика конкрементов почек у пациентов с мочекаменной болезнью

В последние годы по всему миру отмечается тенденция к росту заболеваемости мочекаменной болезнью, а также к увеличению числа рецидивов камнеобразования. Данные по распространенности мочекаменной болезни варьируют от 1 до 20%. В некоторых странах отмечается увеличение показателя до 37%. По причине камнеобразования выделяют инфекционные, неинфекционные и образовавшиеся вследствие генетических заболеваний конкременты. Изменение в микробиоме мочи играет значительную роль в образовании инфекционных конкрементов. Целью работы было изучение современной литературы о роли бактерий в формировании конкрементов в почках. Полученные знания могут быть применены для исследования новых возможностей и улучшения понимания процессов камнеобразования. Нами были проанализированы научные публикации о составе микробиома мочи и конкрементов.

1. Российское общество урологов. Клинические рекомендации «Мочекаменная болезнь». Российское общество урологов; 2019.

2. Каприн А.Д., Аполихин О.И., Сивков А.В. и др. Заболеваемость мочекаменной болезнью в Российской Федерации с 2005 по 2020 гг. Экспериментальная и клиническая урология. 2022;15(2):10–17. https://doi.org/10.29188/2222-8543-2022-15-2-10-17

3. Türk C, Neisius A, Petrik A, et al. EAU Guidelines on Urolithiasis. European Association of Urology; 2020.

4. Thorleifsson G, Holm H, Edvardsson V, et al. Sequence variants in the CLDN14 gene associate with kidney stones and bone mineral density. Nat Genet. 2009;41(8):926–930. PMID: 19561606. https://doi.org/10.1038/ng.404

5. Yang Y, Miao L, Lu Y, Wang S. The genetics of urinary microbiome, an exploration of the trigger in calcium oxalate stone. Front Genet. 2023;14:1260278. PMID: 37854058. PMCID: PMC10579592. https://doi.org/10.3389/fgene.2023.1260278

6. Foley KF, Boccuzzi L. Urine calcium: laboratory measurement and clinical utility. Laboratory Medicine. 2010;41(11):683– 686. https://doi.org/10.1309/lm9so94znbhedntm

7. Laube N, Pullmann M, Hergarten S, Schmidt M, Hesse A. The alteration of urine composition due to stone material present in the urinary tract. Eur Urol. 2003;44(5):595–599. PMID: 14572760. https://doi.org/10.1016/s0302-2838(03)00365-8

8. Gao H, Lin J, Xiong F, Yu Z, Pan S, Huang Y. Urinary microbial and metabolomic profiles in kidney stone disease. Front Cell Infect Microbiol. 2022;12:953392. PMID: 36132987. PMCID: PMC9484321. https://doi.org/10.3389/fcimb.2022.953392

9. Ye Z, Zeng G, Yang H, et al. The status and characteristics of urinary stone composition in China. BJU Int. 2020;125(6):801– 809. PMID: 30958622. https://doi.org/10.1111/bju.14765

10. Robinson TE, Hughes EAB, Wiseman OJ, Stapley SA, Cox SC, Grover LM. Hexametaphosphate as a potential therapy for the dissolution and prevention of kidney stones. J Mater Chem B. 2020;8(24):5215–5224. PMID: 32436557. https://doi.org/10.1039/d0tb00343c

11. Xie J, Huang JS, Huang XJ, et al. Profiling the urinary microbiome in men with calcium-based kidney stones. BMC Microbiol. 2020;20(1):41. PMID: 32111156. PMCID: PMC7049185. https://doi.org/10.1186/s12866-020-01734-6

12. Pazos Pérez F. Uric acid renal lithiasis: new concepts. Contrib Nephrol. 2018;192:116–124. PMID: 29393127. https://doi.org/10.1159/000484286

13. Moussa M, Papatsoris AG, Abou Chakra M, Moussa Y. Update on cystine stones: current and future concepts in treatment. Intractable Rare Dis Res. 2020;9(2):71–78. PMID: 32494553. PMCID: PMC7263987. https://doi.org/10.5582/irdr.2020.03006

14. Hung JA, Li CH, Geng JH, Wu DW, Chen SC. Dyslipidemia increases the risk of incident kidney stone disease in a large Taiwanese population follow-up study. Nutrients. 2022;14(7):1339. PMID: 35405952. PMCID: PMC9000795. https://doi.org/10.3390/nu14071339

15. Стяжкина С.Н., Токарева В.Ю., Гильфанов А.М. Мочекаменная болезнь. Коралловидный камень левой почки. Клинический случай. Столица науки. 2020;(4):150–157.

16. DornbierRA, Bajic P, Van Kuiken M, et al. The microbiome of calcium-based urinary stones. Urolithiasis. 2020;48(3):191–199. PMID: 31240349. https://doi.org/10.1007/s00240-019-01146-w

17. Schwaderer AL, Wolfe AJ. The association between bacteria and urinary stones. Ann Transl Med. 2017;5(2):32. PMID: 28217697. PMCID: PMC5300853. https://doi.org/10.21037/atm.2016.11.73

18. Sivaguru M, Saw JJ, Williams JC Jr, et al. Geobiology reveals how human kidney stones dissolve in vivo. Sci Rep. 2018;8(1):13731. PMID: 30213974. PMCID: PMC6137216. https://doi.org/10.1038/s41598-018-31890-9

19. Sivaguru M, Saw JJ, Wilson EM, et al. Human kidney stones: a natural record of universal biomineralization. Nat Rev Urol. 2021;18(7):404–432. PMID: 34031587. https://doi.org/10.1038/s41585-021-00469-x

20. Zampini A, Nguyen AH, Rose E, Monga M, Miller AW. Defining dysbiosis in patients with urolithiasis. Sci Rep. 2019;9(1):5425. PMID: 30932002. PMCID: PMC6443657. https://doi.org/10.1038/s41598-019-41977-6

21. Lemberger U, Pjevac P, Hausmann B, et al. The microbiome of kidney stones and urine of patients with nephrolithiasis. Urolithiasis. 2023;51(1):27. PMID: 36596939. PMCID: PMC9810570. https://doi.org/10.1007/s00240-022-01403-5

22. Li JKM, Chiu PKF, Ng CF. The impact of microbiome in urological diseases: a systematic review. Int Urol Nephrol. 2019;51(10):1677–1697. PMID: 31301004. https://doi.org/10.1007/s11255-019-02225-y

23. Flannigan RK, Battison A, De S, et al. Evaluating factors that dictate struvite stone composition: a multi-institutional clinical experience from the EDGE Research Consortium. Can Urol Assoc J. 2018;12(4):131–136. PMID: 29319486. PMCID: PMC5905542. https://doi.org/10.5489/cuaj.4804

24. Galán-Llopis JA, Sánchez-Pellicer P, Navarro-López V. Role of microbiome in kidney stone disease. Curr Opin Urol. 2023;33(2):84–89. PMID: 36210763. https://doi.org/10.1097/MOU.0000000000001051

25. Jung HD, Cho S, Lee JY. Update on the effect of the urinary microbiome on urolithiasis. Diagnostics (Basel). 2023;13(5):951. PMID: 36900094. PMCID: PMC10001284. https://doi.org/10.3390/diagnostics13050951

26. Daudon M, Dessombz A, Frochot V, et al. Comprehensive morpho-constitutional analysis of urinary stones improves etiological diagnosis and therapeutic strategy of nephrolithiasis. Comptes Rendus Chimie. 2016;19(11–12):1470–1491. https://doi.org/10.1016/j.crci.2016.05.008

27. Wang Z, Zhang Y, Zhang J, Deng Q, Liang H. Recent advances on the mechanisms of kidney stone formation (review). Int J Mol Med. 2021;48(2):149. PMID: 34132361. PMCID: PMC8208620. https://doi.org/10.3892/ijmm.2021.4982

28. Hong SY, Xia QD, Yang YY, et al. The role of microbiome: a novel insight into urolithiasis. Crit Rev Microbiol. 2023;49(2):177–196. PMID: 35776498. https://doi.org/10.1080/1040841X.2022.2045899

29. Hobbs T, Schultz LN, Lauchnor EG, Gerlach R, Lange D. Evaluation of biofilm induced urinary infection stone formation in a novel laboratory model system. J Urol. 2018;199(1):178–185. PMID: 28827106. https://doi.org/10.1016/j.juro.2017.08.083

30. Barr-Beare E, Saxena V, Hilt EE, et al. The interaction between Enterobacteriaceae and calcium oxalate deposits. PLoS One. 2015;10(10):e0139575. PMID: 26448465. PMCID: PMC4598009. https://doi.org/10.1371/journal.pone.0139575

31. Tavichakorntrakool R, Prasongwattana V, Sungkeeree S, et al. Extensive characterizations of bacteria isolated from catheterized urine and stone matrices in patients with nephrolithiasis. Nephrol Dial Transplant. 2012;27(11):4125–4130. PMID: 22461670. https://doi.org/10.1093/ndt/gfs057

32. Chutipongtanate S, Sutthimethakorn S, Chiangjong W, Thongboonkerd V. Bacteria can promote calcium oxalate crystal growth and aggregation. J Biol Inorg Chem. 2013;18(3):299–308. Published correction appears in J Biol Inorg Chem. 2013;18(4):485– 486. PMID: 23334195. https://doi.org/10.1007/s00775-012-0974-0

33. Kanlaya R, Naruepantawart O, Thongboonkerd V. Flagellum is responsible for promoting effects of viable Escherichia coli on calcium oxalate crystallization, crystal growth, and crystal aggregation. Front Microbiol. 2019;10:2507. PMID: 31749785. PMCID: PMC6848068. https://doi.org/10.3389/fmicb.2019.02507

34. Saw JJ, Sivaguru M, Wilson EM, et al. In vivo entombment of bacteria and fungi during calcium oxalate, brushite, and struvite urolithiasis. Kidney360. 2020;2(2):298–311. PMID: 35373025. PMCID: PMC8740987. https://doi.org/10.34067/KID.0006942020

35. Flannigan R, Choy WH, Chew B, Lange D. Renal struvite stones--pathogenesis, microbiology, and management strategies. Nat Rev Urol. 2014;11(6):333–341. Published correction appears in Nat Rev Urol. 2014;11(6):page after 341. PMID: 24818849. https://doi.org/10.1038/nrurol.2014.99

36. Miller AW, Penniston KL, Fitzpatrick K, Agudelo J, Tasian G, Lange D. Mechanisms of the intestinal and urinary microbiome in kidney stone disease. Nat Rev Urol. 2022;19(12):695–707. PMID: 36127409. https://doi.org/10.1038/s41585-022-00647-5

37. Hong SY, Yang YY, Xu JZ, Xia QD, Wang SG, Xun Y. The renal pelvis urobiome in the unilateral kidney stone patients revealed by 2bRAD-M. J Transl Med. 2022;20(1):431. PMID: 36153619. PMCID: PMC9509602. https://doi.org/10.1186/s12967-022-03639-6

38. Al KF, Joris BR, Daisley BA, et al. Multi-site microbiota alteration is a hallmark of kidney stone formation. Microbiome. 2023;11(1):263. PMID: 38007438. PMCID: PMC10675928. https://doi.org/10.1186/s40168-023-01703-x

39. Liu F, Zhang N, Wu Y, et al. The pelvis urinary microbiome in patients with kidney stones and clinical associations. BMC Microbiol. 2020;20(1):336. PMID: 33153435. PMCID: PMC7643416. https://doi.org/10.1186/s12866-020-01992-4